The extended clearance model and its use for the interpretation of hepatobiliary elimination data

ADMET and DMPK

Volumn 3, Issue 1, 2015, Pages 1-14

  Camenisch, Gian ^a   Riede, Julia ^a,b   Kunze, Annett ^a   Huwyler, Jörg ^b   Poller, Birk ^a   Umehara, Kenichi ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Extended clearance concept classification system; Hepatic elimination; Passive permeability; Transporters

Indexed keywords

EID: 84978238788     PISSN: None     EISSN: 18487718     Source Type: Journal    
DOI: 10.5599/admet.3.1.144     Document Type: Review

References (11)

1. G. Camenisch and K. Umehara, Biopharmaceutics & Drug Disposition 33 (2012) 179-1940.
2. Y. Shitara, H. Sato and Y. Sugiyama, Annual Review of Pharmacology and Toxicology 45 (2005) 689-723.
3. K. Umehara and G. Camenisch, Pharmaceutical Research 29 (2012) 603-617.
4. A. Kunze, B. Poller, J. Huwyler and G. Camenisch, Drug metabolism and drug interactions In Press.
5. D. McGinnity, M. Soars, R. Urbanowicz and R. Riley, Drug Metabolism and Disposition 32 (2004) 1247-1253.
6. D. Hallifax, E. Turlizzi, U. Zanelli and J. Houston, European Journal of Pharmaceutical Sciences 45 (2012) 570-574.
7. A. Kunze, J. Huwyler, B. Poller, H. Gutmann and G. Camenisch, Journal of Pharmaceutical Sciences 103 (2014) 994-1001.
8. L. Benet, G. Amidon, D. Barends, H. Lennernas, J. Polli, V. Shah, S. Stavchansky and L. Yu, Pharmaceutical Research 25 (2008) 483-48.
9. M. Chiba, Y. Ishii and Y. Sugiyama, AAPS Journal 11 (2009) 262-276.
10. D. Hallifax, H. Rawden, N. Hakooz and J. Houston, Drug Metabolism and Disposition 33 (2005) 1852-1858.
11. Y. Shitara, K. Maeda, K. Ikejiri, K. Yoshida, T. Horie and Y. Sugiyama, Biopharmaceutics & Drug Disposition 34 (2013) 45-78.